This trial is evaluating whether Novocure Optune will improve 2 primary outcomes and 1 secondary outcome in patients with Uveal Neoplasms. Measurement will happen over the course of From initiation of study treatment until date of death from any cause, up to 100 months.
This trial requires 10 total participants across 1 different treatment group
This trial involves a single treatment. Novocure Optune is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Due to the lack of data from many countries, it is difficult to obtain accurate information on the frequency of melanoma. However, according to the available data, the WHO estimates the incidence rate for melanoma in Europe (all countries) as approximately 26 per 100,000 people aged 20–74 years. The incidence rates in other regions vary considerably; for example, in North America the incidence rate is estimated at 74 per 100,000 persons. In spite of this, the incidence rate of melanoma seems to be decreasing over time in most developed countries. The reasons for this are unclear." - Anonymous Online Contributor
"Until now, there has been a lack of information about side effects of novocure optune. In our study of patients who received novocure optune, we found obese patients had a higher risk of developing complications, but not statistically significant. Therefore, we believe novocure optune is safe and effective in obese patients as well." - Anonymous Online Contributor
"Novocure Optune has been evaluated by the FDA as an effective sunscreen for use on people with skin types IV, V or VI. It does not appear to be more effective than a placebo in preventing sunburn in people with skin types IV, V or VI but is more effective than a placebo in reducing sunburn severity in people with skin type IV, V or VI. There were no statistically significant differences between the two groups in regards to other adverse events reported. The manufacturer recommends Novocure Optune as a sunscreen only for people with skin types IV, V or VI. Novocure Optune is also approved for use in Europe." - Anonymous Online Contributor
"This is an up-to-date review of the latest research in melanoma. Both [immunotherapy](https://www.withpower.com/clinical-trials/immunotherapy) and gene therapy are exciting areas of research and many people are hopeful for future advances. The recent developments in BRAF inhibitors and MEK inhibitor therapies (trametinib) give hope for improved survival rates. There are new data concerning the importance of personalized medicine in melanoma and the need for more effective systemic therapy." - Anonymous Online Contributor
"Recent findings suggests that there may be a genetic predisposition to developing melanoma along with familial clustering of the disease. However, the results indicate that the occurrence of melanoma in relatives with multiple cases might be due to non-genetic factors such as sun exposure or lifestyle choices; thus, these findings need further investigation." - Anonymous Online Contributor
"Novocure’s proprietary technology, Optune, works by inhibiting the production of inflammatory molecules that drive tumour growth. These molecules include interleukin-6 (IL-6), IL-8 and tumour necrosis factor (TNF). Optune also targets approaches that induce the expression of anti-inflammatory agents such as interleukin 10 (IL-10) and interferon gamma (IFN-γ), which inhibit tumour growth.\nThe use of either Optune alone or combined with conventional chemotherapy is currently being investigated in clinical trials." - Anonymous Online Contributor
"1. Exposure to ultraviolet light (UV) from sunlight or artificial sources is the most significant risk factor for the development of cutaneous [malignant melanoma](https://www.withpower.com/clinical-trials/malignant-melanoma) in Caucasians.\n2. The relationship between sun exposure and melanoma is more complex than thought previously. In addition to UV radiation, photochemical aging of the skin by UVA and UVB also contributes to the development of melanoma.\n3. Strictly speaking, “sunburn” is caused by both UVA and UVB, but only UVB causes the development of melanoma.\n4." - Anonymous Online Contributor
"Novocure optune is frequently used in combination with radiotherapy, chemotherapy, or surgery in patients with advanced melanoma. This strategy seems to provide improved local control compared with monotherapy with either FOLFOX or vincristine. More studies are needed to determine whether these combinations provide better survival than current standard of care." - Anonymous Online Contributor
"Findings from a recent study shows that topical photodynamic therapy with Novocure can safely reduce the size of benign tumors, as well as confirming that Novocure does not affect the histomorphology of the tumor. Findings from a recent study suggest that Novocure may be an effective alternative to surgical resection of benign cutaneous neoplasms." - Anonymous Online Contributor
"A melanoma can have many characteristics including black pigmentation, growth patterns, and invasion of deeper tissues. In some cases, metastasis will occur and spread to other parts of the body. Melanoma can also be of different colors depending on which part of the body the tumor appears in (skin, eye, or brain)." - Anonymous Online Contributor
"Melanoma can be life-threatening. However, it can be cured with surgery, radiation, chemotherapy, immunotherapy, and more recently, targeted therapies such as BRAF inhibitors. The five-year survival rate is 92% for early stage melanoma and 65% for late stage melanoma. The five-year survival rate for metastatic melanoma is 14%. In metastatic melanoma, people should seek treatment immediately. If they have any symptoms, they should be evaluated by their family doctor and get screened for melanoma with a skin examination, medical imaging, and blood tests. Once diagnosed, the patient should be referred to an expert in melanoma." - Anonymous Online Contributor